Quantcast

Latest Pseudomonas Stories

2009-06-11 11:48:43

Scottish and U.S. scientists say their discovery of how some bacteria protect themselves when they are under attack might lead to new antimicrobial drugs. The 25-year study -- led by University of Aberdeen Professor Ian Booth and researcher Tarmo Roosild of the Nevada Cancer Institute in Las Vegas -- determined the mechanics of channels in bacteria that stay shut if all is normal and are triggered to open if they need to mount a defense. The scientists said their finding could result in the...

2009-05-05 06:00:00

First Diagnostic Test for Identifying E. coli, K. pneumoniae and P. aeruginosa Directly from Positive Blood Cultures PNA FISH Provides Critical Results 24-48 Hours Sooner Than Conventional Methods to Help Clinicians Improve Care and Outcomes for 100,000 Patients with Gram-Negative Bloodstream Infections WOBURN, Mass., and VEDBAEK, Denmark, May 5 /PRNewswire/ -- AdvanDx today announced it received FDA 510(k) clearance for EK/P. aeruginosa PNA FISH(R) to identify Escherichia coli and/or K....

2009-04-25 10:54:51

Dartmouth Medical School researchers have devised a novel approach for thwarting the relentless bacterial infections that thrive in the lungs of people with cystic fibrosis (CF), unlocking new possibilities against a tenacious and toxic hallmark of the common genetic disease. Combining a mainstay antibiotic with drugs to deprive the bacteria of iron, which facilitates their persistent growth, appears to boost infection killing, they found. Their research, reported in the American Journal of...

2009-04-21 09:00:00

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the...

2009-04-13 15:35:02

U.S. medical researchers say they have discovered a lack of the mineral phosphate can turn a common bacterium -- Pseudomonas aeruginosa -- into a killer. University of Chicago scientists said their finding could lead to new drugs that would disarm the increasingly antibiotic-resistant pathogen rather than kill it. Pseudomonas aeruginosa, one of the most serious hospital-acquired pathogens, is a common cause of lung infections. It is found in the intestinal tract of 20 percent of all Americans...

2009-04-09 07:44:23

'Red Death' provides clues about how P. aeruginosa attacks hostLack of an adequate amount of the mineral phosphate can turn a common bacterium into a killer, according to research to be published in the April 14, 2009, issue of the Proceedings of the National Academies of Science. The findings could lead to new drugs that would disarm the increasingly antibiotic-resistant pathogen rather than attempting to kill it. Pseudomonas aeruginosa is one of the most serious hospital-acquired...

2009-03-26 03:30:00

PARIS, March 26 /PRNewswire-FirstCall/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB). Novexel's SAB is chaired by Dr. David Shlaes who sits on the Company's board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana...

2009-03-24 08:44:04

Researchers at National Jewish Health have discovered a promising strategy for destroying the molecular scaffolding that can make Pseudomonas bacterial infections extremely difficult to treat in cystic fibrosis patients, wearers of contact lenses, and burn victims. Jerry Nick, MD, Associate Professor of Medicine at National Jewish Health, and his colleagues report in the April 2009 issue of The Journal of Medical Microbiology that a long string of aspartic acid molecules disrupts the...

2009-03-23 23:01:00

SAN DIEGO, March 24 /PRNewswire/ -- Calixa Therapeutics Inc. today announced positive results from a Phase 1 trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity. The results from this first Phase 1 study demonstrated that CXA-101 was well tolerated, with a clinical and laboratory safety profile similar to that of marketed cephalosporin antibiotics. No dose-limiting toxicity was observed, even at the highest dose regimen evaluated....

2009-03-18 09:14:15

The unexpected behaviour of a family of "superbugs" called the Burkholderia cepacia complex (Bcc) could have implications for the treatment of cystic fibrosis (CF) patients. CF patients produce large quantities of sticky mucus in their lungs that is difficult to expel and is easily infected by bacteria. A recent treatment for CF, inhalation of a sugar called mannitol, works by attracting moisture into the lungs. This thins the mucus making it easier to disperse. However, recent research by...


Latest Pseudomonas Reference Libraries

0_85d9abd5d0844260722ff2e72fcc9f5a
2011-04-25 21:18:54

Pseudomonas aeruginosa is a common bacterium that can cause disease in animals and humans. It can be found in soil, water, skin flora, and most man-made environments throughout the world. It thrives in normal or hypoxic atmospheres; due to this it has colonized many natural and artificial environments. It can infect animals with damaged tissue or people with reduced immunity. Symptoms are generalized inflammation and sepsis. It can be fatal if colonization occurs in critical body organs,...

More Articles (1 articles) »
Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.